StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Payer coverage expansion reduces reimbursement risk and can accelerate test adoption; historical moves in diagnostic trials and MRD tests show volume uplift as coverage broadens, though ramp can take quarters.
What happened, with direct paths to the underlying reporting
NeoGenomics announced CMS MolDX expanded RaDaR ST coverage to monitor immunotherapy in late-stage solid tumors, a payer milestone. The third Medicare-covered RaDaR ST indication, with two more submissions pending, could boost adoption as immunotherapy remains standard in many cancers. If uptake accelerates, RaDaR ST testing could lift near-term revenue and volume.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.